Tech Company Financing Transactions

Decoy Therapeutics Funding Round

Decoy Therapeutics closed a funding round on 3/11/2026. Investors included GV.

Transaction Overview

Company Name
Announced On
3/11/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The platform will support: Tiered protein folding pipelines, enabling dynamic trade-offs between speed and structural accuracy; Advanced molecular dynamics simulations with GPU acceleration and AI-enhanced sampling; Diffusion-based conformational ensemble generation to improve structural plausibility; Automated algorithm selection and precision optimization to balance computational efficiency and model fidelity; Real-time monitoring, visualization of 3D structures and performance benchmarking through a unified interface.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
One Broadway, 14th Floor
Cambridge, MA 02142
USA
Phone
Undisclosed
Email Address
Overview
Decoy Therapeutics (Decoy Tx) believes everyone deserves to enjoy family, friends, travel and experiences without worrying about getting sick. We further believe that too many patients die from malignant diseases due to a lack of effective, targeted therapeutics. Lastly, we believe in developing medicines that are accessible and affordable to everyone, everywhere--empowering communities worldwide to lead healthier lives.
Profile
Decoy Therapeutics LinkedIn Company Profile
Social Media
Decoy Therapeutics Company Twitter Account
Company News
Decoy Therapeutics News
Facebook
Decoy Therapeutics on Facebook
YouTube
Decoy Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chairman
William McVicar
  William McVicar LinkedIn Profile  William McVicar Twitter Account  William McVicar News  William McVicar on Facebook
Chief Executive Officer
Rick Pierce
  Rick Pierce LinkedIn Profile  Rick Pierce Twitter Account  Rick Pierce News  Rick Pierce on Facebook
Chief Financial Officer
Mark Rosenblum
  Mark Rosenblum LinkedIn Profile  Mark Rosenblum Twitter Account  Mark Rosenblum News  Mark Rosenblum on Facebook
Chief Scientific Officer
Barb Hibner
  Barb Hibner LinkedIn Profile  Barb Hibner Twitter Account  Barb Hibner News  Barb Hibner on Facebook
Chief Technical Officer
Michael Lipp
  Michael Lipp LinkedIn Profile  Michael Lipp Twitter Account  Michael Lipp News  Michael Lipp on Facebook
Controller
Annie Yan
  Annie Yan LinkedIn Profile  Annie Yan Twitter Account  Annie Yan News  Annie Yan on Facebook
VP - Bus. Development
Peter Marschel
  Peter Marschel LinkedIn Profile  Peter Marschel Twitter Account  Peter Marschel News  Peter Marschel on Facebook
VP - Operations
Jodi Cooper
  Jodi Cooper LinkedIn Profile  Jodi Cooper Twitter Account  Jodi Cooper News  Jodi Cooper on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/11/2026: Ernesta venture capital transaction
Next: 3/11/2026: Bliss venture capital transaction

 

Share this article

 


Where The Data Comes From

We document every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary